Bausch Health Companies Inc. vs Merus N.V.: SG&A Expense Trends

SG&A Expense Trends: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial health of companies is crucial. Bausch Health Companies Inc. and Merus N.V. present a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Bausch Health's SG&A expenses have shown a steady increase, peaking in 2023 with a 44% rise from 2014. This trend reflects the company's expansive operational strategies and market penetration efforts. In contrast, Merus N.V., a smaller player, has seen its SG&A expenses grow exponentially, with a staggering 1,454% increase over the same period. This sharp rise underscores Merus's aggressive investment in research and development, crucial for its growth in the competitive biotech industry.

These trends highlight the diverse strategies employed by companies in managing operational costs while striving for market leadership.